Welcome to 2026 Analyst Day Matt Bacso VP, Investor Relations © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 1 This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. Exchange Commission ("SEC"), including the Ann ...

SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after ...

Core Insights - PROCEPT BioRobotics is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at two investor conferences in March 2026, indicating active engagement with the investment community [1][2] Company Overview - PROCEPT BioRobotics aims to revolutionize the treatment of Benign Prostatic Hyperplasia (BPH) globally by partnering with urologists [3] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting a significant market opportunity for the company [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference [2] - A live webcast of each event will be available on the company's website, with recordings archived for at least 90 days [2] - Specific event details include a fireside chat on March 2 at 11:40 am ET in Boston, MA, and another on March 10 at 8 am ET in Miami, FL [4]

Company Overview - PROCEPT BioRobotics is a healthcare technology company specializing in robotic surgical systems for minimally invasive urology procedures, particularly targeting benign prostatic hyperplasia (BPH) treatment [6][9] - The company utilizes proprietary image-guided robotic systems to enhance patient outcomes and hospital efficiency, with a competitive edge stemming from its innovative Aquablation therapy and a growing installed base [6][9] Financial Performance - As of January 26, PROCEPT BioRobotics had a market capitalization of $1.65 billion, with a trailing twelve months (TTM) revenue of $299.91 million and a net income loss of $84.58 million [4] - The company reported a 43% year-over-year revenue increase in the third quarter, amounting to $83.3 million, and a gross margin expansion to 65% [11] - Management provided revenue guidance for 2026, projecting between $410 million and $430 million, indicating potential growth of up to 32% from 2025 levels [11] Recent Transactions - Chicago Capital disclosed a reduction in its stake in PROCEPT BioRobotics by 377,850 shares in the fourth quarter, translating to an estimated transaction value of $12.53 million [2][3] - Following this transaction, Chicago Capital's remaining stake in PROCEPT was valued at $37.47 million, with the position now accounting for 0.93% of its 13F assets, down from 1.38% in the previous quarter [2][3] Stock Performance - As of January 26, PROCEPT BioRobotics shares were priced at $29.61, reflecting a significant decline of 60.4% over the past year, contrasting sharply with the S&P 500's approximate 14% gain during the same period [3][11] - The stock's performance has raised concerns regarding operating losses, high spending, and the pace at which growth can lead to sustainable profitability, as evidenced by an adjusted EBITDA loss of $7.4 million in the quarter [11]

Group 1 - The company, PROCEPT BioRobotics Corporation, will report its financial results for Q4 2025 on February 24, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1] - An in-person investor day event is scheduled for February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with advance registration recommended [2] - Live webcasts of both the financial results and investor day will be available on the company's website, with recordings archived for at least 90 days [3] Group 2 - PROCEPT BioRobotics aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [4] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy, designed for effective treatment of lower urinary tract symptoms in men [4] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [4]

Core Viewpoint - PROCEPT BioRobotics is focused on advancing patient care in urology through innovative robotic solutions, particularly in the treatment of benign prostatic hyperplasia (BPH) [3]. Company Overview - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3]. - The company aims to revolutionize BPH treatment globally in partnership with urologists, emphasizing the delivery of effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH [3]. - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3]. - The company has developed a substantial body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3]. Upcoming Events - Management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2 at 8:30 a.m. Eastern Time [1]. - A live webcast of the event will be available on the company's website, with recordings archived for at least 90 days [2].

Core Viewpoint - PROCEPT BioRobotics Corporation is recognized as a fast-growing small-cap stock, with analysts maintaining a Buy rating despite a price target reduction from $55 to $50 following strong fiscal Q3 2025 results [1][2]. Financial Performance - The company reported a revenue increase of 42.76% to $83.33 million, exceeding estimates by $2.56 million [2]. - The earnings per share (EPS) of negative $0.38 also surpassed consensus expectations by $0.04 [2]. Product and Market Demand - Revenue growth is attributed to strong demand for the HYDROS Robotic System, which saw a year-over-year growth of 43%, alongside increasing adoption of Aquablation therapy [2][3]. - PROCEPT BioRobotics develops the AQUABEAM Robotic System, a surgical robot that utilizes real-time imaging and a heat-free water jet for precise prostate tissue removal [4]. Analyst Insights - Analyst Matthew O'Brien noted that the company's Q3 performance was better than expected, with sales forecasts for 2025 and 2026 aligning closely with Wall Street's expectations [3]. - Concerns regarding soft utilization performance and investor destocking are viewed as temporary issues, attributed to internal changes within the company [3].

Core Insights - PROCEPT BioRobotics Corporation reported a strong performance with a 43% year-over-year global revenue growth for Q3 2025, driven by increased demand for the HYDROS® Robotic System and Aquablation therapy adoption [3][4]. Financial Performance - Total revenue for Q3 2025 was $83.3 million, a 43% increase compared to Q3 2024 [4][9]. - U.S. revenue reached $73.9 million, reflecting a 42% growth year-over-year, primarily from system sales and increased handpiece revenue [4][9]. - U.S. handpiece and consumable revenue was $44.4 million, up 50% from the previous year, while system revenue was $24.7 million, a 26% increase [4][9]. - International revenue for the quarter was $9.4 million, marking a 53% increase compared to the prior year [4][9]. Gross Margin and Operating Expenses - Gross margin improved to 65% in Q3 2025 from 63% in the prior year, attributed to operational efficiencies despite increased tariff expenses [5]. - Operating expenses rose to $77.2 million from $59.3 million in the prior year, driven by expansion of the commercial organization and increased R&D and administrative expenses [6]. Net Loss and Adjusted EBITDA - The net loss for Q3 2025 was $21.4 million, slightly higher than the $21.0 million loss in Q3 2024 [7]. - Adjusted EBITDA loss improved to $7.4 million from a loss of $12.4 million in the prior year [7][18]. Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling $297.3 million [7]. Full Year Guidance - The company maintains its revenue guidance for the full year 2025 at approximately $325.5 million, representing a 45% growth over the previous year [8][9]. - For 2026, the projected revenue is between $410 million and $430 million, indicating a growth of 26% to 32% compared to 2025 [10][9].

Core Insights - Chicago Capital, LLC increased its stake in Procept BioRobotics by 999,873 shares, totaling 1,568,845 shares valued at $55.99 million as of quarter-end [1][2] - Procept BioRobotics' stock price was $34.61 as of October 21, 2025, reflecting a 48.57% decline year-over-year and underperforming the S&P 500 by 63.63 percentage points [2] - The company reported a revenue increase of 48% year-over-year in Q2, raising its full-year revenue outlook for 2025 to $325.5 million, a 45% increase over 2024 [9][10] Company Overview - Procept BioRobotics specializes in surgical robotics for urology, focusing on treating benign prostatic hyperplasia (BPH) with its AquaBeam Robotic System [4][5] - The company has a market capitalization of $1.95 billion and a trailing twelve months (TTM) revenue of $274.95 million, with a net income of -$84.15 million [3] Investment Rationale - Chicago Capital's significant increase in investment suggests confidence in Procept BioRobotics' growth potential despite recent stock price declines [7][11] - The company's rapid sales growth and attractive price-to-sales ratio of seven may indicate a compelling investment opportunity [10][11]

Company Overview - PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care in urology by developing transformative solutions [3] - The company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), independent of prostate size and surgeon experience [3] Financial Reporting - The company will report its financial results for the third quarter of 2025 after market close on November 4, 2025 [1] - A conference call will be hosted by the company's management at 4:30 p.m. Eastern Time on the same day [1] Clinical Evidence - PROCEPT BioRobotics has developed a significant body of clinical evidence with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [3]